| Patents for A61K - Preparations for medical, dental, or toilet purposes (29,449) |
|---|
| 07/07/2005 | US20050148605 Modulation of protein tyrosine kinases for treatment of diseases with prodrugs |
| 07/07/2005 | US20050148593 Compounds, compositions, and methods |
| 07/07/2005 | US20050148591 Tartrate salts of 5,8,14-triazatetracyclo [10.3.1.02,11.04,9]-hexadeca-2(11),3,5,7,9-pentaen and pharmaceutical compositions thereof |
| 07/07/2005 | US20050148589 Compositions of a cyclooxygenase-2 selective inhibitor and a neurotrophic factor-modulating agent for the treatment of central nervous system mediated disorders |
| 07/07/2005 | US20050148556 Compositions and methods for increasing HDL and HDL-2b levels |
| 07/07/2005 | US20050148552 Administering low concentration tetracycline compound; below antibacterial activity level |
| 07/07/2005 | US20050148532 14-3-3 zeta over-expression as a poor prognosis factor, and a therapeutic target in multiple cancer types |
| 07/07/2005 | US20050148523 Such as saquinavir, ritonavir, indinavir, nelfinavir, fosamprenavir, amprenavir, and lopinavir |
| 07/07/2005 | US20050147670 Oral disintegrating dosage forms |
| 07/07/2005 | US20050147607 administering interleukin antagonists, for prophylaxis of respiratory system disorders |
| 07/07/2005 | US20050147593 Targeting cells expressing low molecular weight protein tyrosine kinase (LMW-PTP) utilizing nucleic acid operatively associated with delivery vehicle |
| 07/07/2005 | US20050147580 Therapy for kidney diseasel removal phosphates; gastrointestinal disorders |
| 07/07/2005 | US20050144741 Composition for dyeing keratin fibres with a cationic direct dye and a thickening polymer |
| 07/07/2005 | CA2550298A1 Reduction of toxicity of multi-targeting antifolates |
| 07/07/2005 | CA2549103A1 Use of a fatty acid composition comprising at least one of epa and dha or any combinations thereof |
| 07/06/2005 | EP1549763A2 Prophylactic and therapeutic hiv aptamers |
| 07/06/2005 | EP1549340A1 Biofunctional cpg or oligo-/polynucleotide and toxin or enterotoxin containing composition |
| 07/06/2005 | EP1549332A2 Modified asialo-interferons and uses thereof |
| 07/06/2005 | EP1549323A2 Conjugates comprising central nervous system active drug |
| 07/06/2005 | EP1549315A2 Dihydroxypyridopyrazine-1,6-dione compounds useful as hiv integrase inhibitors |
| 07/06/2005 | EP1549300A2 Nitric oxide and its biomedical significance |
| 07/06/2005 | EP1549246A2 Antibiotic microspheres for treatment of infections and osteomyelitis |
| 07/06/2005 | EP1140145B1 Novel exendin agonist formulations and methods of administration thereof |
| 07/06/2005 | CN1635904A 肺炎链球菌疫苗 Streptococcus pneumoniae vaccine |
| 07/06/2005 | CN1635892A Ziprasidone composition and synthetic controls |
| 07/06/2005 | CN1635870A Medicinal aerosol formulations |
| 07/06/2005 | CN1209112C Smilagenin and anzurogenin-D for treating Alzheimer's disease |
| 07/06/2005 | CN1209098C Methods and devices for providing prolonged drug therapy |
| 07/05/2005 | US6914056 Pharmaceutical compositions comprising cyclic glycerophosphates and analogs thereof for promoting neural cell differentiation |
| 07/05/2005 | US6914055 Cancer therapeutic formulation having reduced toxicity comprising a galactomannan, and a chemotherapeutic agent |
| 07/05/2005 | US6914049 IGF-binding protein-derived peptide or small molecule |
| 07/05/2005 | US6913770 Process for the extraction of valerian root |
| 07/05/2005 | US6913768 Attention deficit disorders |
| 07/05/2005 | US6913743 Near infrared imaging agent |
| 07/05/2005 | CA2253545C Phosphatidic acid-comprising compositions |
| 07/05/2005 | CA2165446C Use of ropivacaine in the manufacture of a pharmaceutical with analgetic effect with minimal motor blockade |
| 06/30/2005 | WO2005058361A1 USE OF mGluR1 ANTAGONISTS FOR THE TREATMENT OF GERD |
| 06/30/2005 | WO2005058323A1 USE OF METABOTROPIC GLUTAMATE RECEPTOR 1 (mGLuR1) ANTAGONISTS FOR THE TREATMENT OF IRRITABLE BOWEL SYNDROME (IBS) |
| 06/30/2005 | WO2005058322A1 USE OF METABOTROPIC GLUTAMATE RECEPTOR 1 (mGLuR1) ANTAGONISTS FOR THE TREATMENT OF GASTROINTESTINAL DISORDERS |
| 06/30/2005 | WO2005058252A2 Glp-1 pharmaceutical compositions |
| 06/30/2005 | WO2005058251A2 Hla-dr-specific antibodies, compositions and methods |
| 06/30/2005 | WO2005058250A2 Methods of administering water-soluble prodrugs of propofol for extended sedation |
| 06/30/2005 | WO2005058249A2 Quinoa protein concentrate, production and functionality |
| 06/30/2005 | WO2005058248A2 A method of treating hiv infection in atazanavir resistant patients using a combination of atazanavir and another protease inhibitor |
| 06/30/2005 | WO2005058247A2 Method for preparing radiolabeled thymidine having low chromophoric byproducts |
| 06/30/2005 | WO2005058246A2 Method for preparing radiolabeled thymidine |
| 06/30/2005 | WO2005058245A2 Synthetic process |
| 06/30/2005 | WO2005058244A2 Novel anti-dc-sign antibodies |
| 06/30/2005 | WO2005058243A2 Methods for treating cancer using vascular endothelial cell growth inhibitor vegi-192a |
| 06/30/2005 | WO2005058242A2 Chewable soft capsules containing ungelatinized starch |
| 06/30/2005 | WO2005058239A2 Apparatus and methods for forming and securing gastrointestinal tissue folds |
| 06/30/2005 | WO2005058238A2 Antimicrobial composition |
| 06/30/2005 | WO2005058237A2 Treatment of aids |
| 06/30/2005 | WO2005058236A2 Cab molecules |
| 06/30/2005 | WO2005058235A2 Methods using sulodexide for the treatment of bladder disease |
| 06/30/2005 | WO2005058234A2 Methods and compositions relating to ccr5 antagonist, ifn-ϝ and il-13 induced inflammation |
| 06/30/2005 | WO2005058231A2 Rifamycin analogs and uses thereof |
| 06/30/2005 | WO2005058229A2 Antiviral proteins with improved properties and methods therefor |
| 06/30/2005 | WO2005051328A3 Amelioration of macular degeneration and other ophthalmic diseases |
| 06/30/2005 | WO2005041854A3 Composition for the cosmetic treatment of age-related dermatological symptoms |
| 06/30/2005 | WO2005039492A3 Improved combination bacteriolytic therapy for the treatment of tumors |
| 06/30/2005 | WO2005037227A3 Selective cox-2 inhibitors |
| 06/30/2005 | WO2005037218A3 Lentiviral vector delivery of il-21 for treatment of cancer |
| 06/30/2005 | WO2005034878A3 Pyrovalerone analogs and therapeutic uses thereof |
| 06/30/2005 | WO2005032484A3 Alkoxy substituted imidazoquinolines |
| 06/30/2005 | WO2005032475A3 In vivo efficacy of ny-eso-1 plus adjuvant |
| 06/30/2005 | WO2005030148A3 Tetrahydroindolone derivatives for treatment of neurological conditions |
| 06/30/2005 | WO2005027838A3 Synthesis and manufacture of pentostatin and its precursors, analogs and derivatives |
| 06/30/2005 | WO2005025508A3 Magnetically targetable particles comprising magnetic components and biocompatible polymers for site-specific delivery of biologically active agents |
| 06/30/2005 | WO2005025494A3 Vaccine immunotherapy for immune suppressed patients |
| 06/30/2005 | WO2005018560A3 Methods of reducing risk of infection from pathogens |
| 06/30/2005 | WO2005016277A3 Arylsulfonamidobenzylic compounds |
| 06/30/2005 | WO2005013890A3 Function and regulation of angiopoietin-3/angiopoietin-4 |
| 06/30/2005 | WO2005009369A3 A ca6 antigen-specific cytotoxic conjugate and methods of using the same |
| 06/30/2005 | WO2005009350A9 Fugetactic proteins, compositions and methods of use |
| 06/30/2005 | WO2005004816A3 Color stabilization of hydroquinone hydroxyethyl ether products |
| 06/30/2005 | WO2005002529A3 Immunogenicity-reduced anti-cr1 antibody and compositions and methods of treatment based thereon |
| 06/30/2005 | WO2004110392A3 Compositions and methods for treating coronavirus infection and sars |
| 06/30/2005 | WO2004108080A3 Method for treating diseases using hsp90-inhibiting agents in combination with immunosuppressants |
| 06/30/2005 | WO2004103293A3 Modulators of the p2y10 receptor useful in altering t lymphocyte function |
| 06/30/2005 | WO2004100960A8 Anti-inflammatory phosphonate compounds |
| 06/30/2005 | WO2004096161A3 Pharmaceutical compositions for treating painful neuropathy and methods of treating same |
| 06/30/2005 | WO2004096119A3 Topical pharmaceutical compositions, methods of manufacture thereof and articles of manufacture containing same |
| 06/30/2005 | WO2004093788A3 Desmoglein 4 is a novel gene involved in hair growth |
| 06/30/2005 | WO2004084809A3 Neuroprotective macrocylic compounds and methods for their use |
| 06/30/2005 | WO2004058178A3 Uses of mammalian cytokine; related reagents |
| 06/30/2005 | WO2004054502A3 Modulation of tek expression |
| 06/30/2005 | WO2004017918A9 Method of preparing dry powder inhalation compositions |
| 06/30/2005 | US20050144657 Transfecting rhesus papillomavirus (RhPV) genome into raft culture of rhesus cervical cells or foreskin keratinocytes with DNA molecule; inducing heat shock protein 40 and 70 expression enhancing viron growth |
| 06/30/2005 | US20050143450 6-methyl-1,3,8-trichlorodibenzofuran; aryl hydrocarbon receptor (AhR) agonist; chemotherapy for benign and malignant prostatic hypertrophy (BPH and MPH), androgen responsive and nonresponsive neoplasm |
| 06/30/2005 | US20050143449 Non-steroidal farnesoid X receptor modulators and methods for the use thereof |
| 06/30/2005 | US20050143446 Compounds for use as antigrowth agents or antitumor agents and with solvents |
| 06/30/2005 | US20050143420 administering immunomodulatory compounds; sickle cell anemia or beta -thalassemia; 4-(Amino)-2-(2,6-dioxo(3-piperidyl))-isoindoline-1,3-dione; 3-(4-amino-1-oxo-1,3-dihydroisoindol-2-yl)-piperidine-2,6-dione |
| 06/30/2005 | US20050143371 Beta-carboline compounds and analogues thereof as mitogen-activated protein kinase-activated protein kinase-2 inhibitors |
| 06/30/2005 | US20050143359 Methods of hormonal treatment utilizing contraceptive regimens with continuous estrogen administration |
| 06/30/2005 | US20050143350 Combination drug therapy to treat obesity |
| 06/30/2005 | US20050143317 Compounds and methods for treatment of thrombosis |
| 06/30/2005 | US20050143292 Glycopegylated erythropoietin |
| 06/30/2005 | US20050142617 gene related to bone density; possible use in the drug screening, treatment, and diagnosis of bone disorders such as osteoporosis |
| 06/30/2005 | US20050142225 Stabilised pharmaceutical compositions on the basis of polyoxyethlated castor oil and method for manufacturing the same |